Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Targeted Oncology
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed...